Cargando…
P1538: INHIBITION OF COMPLEMENT C1S WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): RESULTS FOLLOWING 9-WEEK WASHOUT PERIOD IN PHASE 3 CARDINAL STUDY (NCT03347396)
Autores principales: | Röth, A., Barcellini, W., D’Sa, S., Miyakawa, Y., Broome, C. M., Michel, M., Kuter, D. J., Jilma, B., Tvedt, T. H. A., Weitz, I. C., Sourdille, T., Wang, J., Vagge, D. S., Kralova, K., Shafer, F., Wardecki, M., Lee, M., Berentsen, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430830/ http://dx.doi.org/10.1097/01.HS9.0000849008.10618.c0 |
Ejemplares similares
-
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results
por: Röth, Alexander, et al.
Publicado: (2022) -
Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up
por: Röth, Alexander, et al.
Publicado: (2023) -
P1486: SERUM BIOMARKERS AS PREDICTORS OF RESPONSE TO SUTIMLIMAB IN COLD AGGLUTININ DISEASE (CAD): A POST-HOC ANALYSIS OF PHASE 3 CARDINAL AND CADENZA STUDY DATA
por: Barcellini, Wilma, et al.
Publicado: (2023) -
P1469: INHIBITION OF COMPLEMENT C1S WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): RESULTS FOLLOWING 9-WEEK OFF-TREATMENT PERIOD (WASHOUT) IN THE PHASE 3 CADENZA STUDY
por: Röth, Alexander, et al.
Publicado: (2023) -
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial
por: Röth, Alexander, et al.
Publicado: (2022)